Separately, Liberum Capital reissued an under review rating on shares of Shield Therapeutics in a research note on Monday, February 5th.
LON:STX opened at GBX 16.50 ($0.23) on Friday. Shield Therapeutics has a 1 year low of GBX 15 ($0.21) and a 1 year high of GBX 168.50 ($2.38).
COPYRIGHT VIOLATION WARNING: “Shield Therapeutics’ (STX) Under Review Rating Reiterated at Peel Hunt” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/04/16/shield-therapeutics-stx-earns-under-review-rating-from-peel-hunt.html.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.